Form 4: Shattuck Labs Director Acquires Significant Stock Options

Shattuck Labs Director Clay B. Siegall acquired 33,150 stock options with an exercise price of $0.82, vesting over one year or prior to the next annual meeting.

Summary

• Clay B. Siegall, a Director of Shattuck Labs, Inc. (STTK), acquired stock options.
• The transaction occurred on July 14, 2025.
• The options grant the right to purchase a total of 33,150 shares of Shattuck Labs common stock.
• The exercise price for these options is $0.82 per share.
• The options will vest in full on the earlier of the one-year anniversary of the grant date (July 14, 2026) or immediately prior to the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Mr. Siegall's continued service to Shattuck Labs.
• The options have an expiration date of July 14, 2035.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director typically indicates confidence in the company's future prospects and aligns management's interests with shareholder value creation, which is generally viewed positively.

Positives

• Director Clay B. Siegall acquired 33,150 stock options, which can be interpreted as a signal of confidence in the company's future performance and aligns his interests with long-term shareholder value.
• The options have a long expiration date of July 14, 2035, providing a significant window for potential value realization if the stock price appreciates.

Negatives

• NA

Risks

• The value of the acquired stock options is directly tied to the future market price of Shattuck Labs, Inc. common stock, meaning the options could become worthless if the stock price does not exceed the exercise price of $0.82.
• Vesting of the options is subject to the reporting person's continued service to the Issuer, posing a risk if service is terminated before the vesting conditions are met.

Future Outlook

The stock options granted to Director Clay B. Siegall are designed to incentivize long-term commitment and align his interests with future shareholder value creation, as they vest over time and have a long expiration period, indicating a forward-looking compensation strategy.

Industry Context

Insider stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The acquisition of stock options by Director Clay B. Siegall represents a compensation-related transaction between the company and a related party, which is a standard practice for executive and director remuneration.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock options as a positive signal, indicating management's belief in the company's long-term growth and potential for increased shareholder value.
• Employees are not directly impacted by this specific transaction, but it reflects standard executive compensation practices within the company.

Next Steps

• The stock options will vest in full on the earlier of July 14, 2026, or immediately prior to Shattuck Labs' next annual meeting of stockholders, subject to continued service.
• Clay B. Siegall may choose to exercise these options at any point after vesting and before the expiration date of July 14, 2035, provided the stock price is favorable.

Key Dates

Recommendation

Keywords

Shattuck Labs, STTK, Stock Options, Insider Transaction, Director Compensation, Equity Compensation, Beneficial Ownership, SEC Form 4